Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company (SPAC) formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more operating businesses. DMAA does not have commercial operations of its own and does not generate operating revenue. Its strategic focus, as disclosed in regulatory filings, is on identifying targets within the pharmaceuticals, healthcare, and domestic drug manufacturing ecosystem, with an emphasis on strengthening U.S.-based pharmaceutical supply chains.
The company was incorporated in 2020 and completed its initial public offering (IPO) in the United States, raising capital to be held in trust while it seeks an acquisition target. DMAA’s positioning centers on the policy-driven and market-supported trend toward reshoring pharmaceutical manufacturing to the United States, particularly for essential medicines and active pharmaceutical ingredients (APIs). As of the most recent public disclosures, DMAA has not completed a business combination. Data inconclusive based on available public sources regarding any definitive merger agreement.
Business Operations
DMAA’s operations are limited to activities necessary to identify, evaluate, and negotiate a potential business combination. The company’s revenue model is contingent upon the successful completion of a merger, at which point it would derive revenue from the operating activities of the acquired business. Prior to a transaction, DMAA’s assets consist primarily of cash and U.S. Treasury securities held in a trust account, as disclosed in SEC filings.
The company does not maintain domestic or international commercial operations, proprietary technologies, or operating subsidiaries at this stage. Its activities are overseen by management and the board, with support from legal, financial, and advisory firms. DMAA has not disclosed any binding partnerships, joint ventures, or controlling interests in operating companies. Data inconclusive based on available public sources regarding non-binding letters of intent.
Strategic Position & Investments
DMAA’s stated strategic direction is to acquire a company aligned with U.S.-based pharmaceutical manufacturing, healthcare supply chains, or related life sciences services. The strategy emphasizes businesses that may benefit from government incentives, national security considerations, and long-term demand for domestically produced drugs. This positioning reflects broader industry and policy trends rather than proprietary competitive advantages.
As of the latest publicly available information, DMAA has not announced any completed acquisitions, controlling investments, or portfolio companies. Funds raised in the IPO remain allocated for a future transaction, subject to shareholder approval and regulatory requirements. Any involvement in emerging technologies or advanced manufacturing remains prospective and unverified. Data inconclusive based on available public sources.
Geographic Footprint
DMAA is headquartered in the United States and is listed on a U.S. securities exchange. Its geographic footprint is currently limited to its corporate and regulatory presence, as it does not operate manufacturing facilities, research centers, or service operations.
The company’s investment mandate is primarily focused on the United States, with an emphasis on domestic operations and supply chains. International exposure would depend entirely on the geographic scope of a future acquisition. No confirmed international operations or investments have been disclosed.
Leadership & Governance
DMAA is led by an experienced sponsor team with backgrounds in healthcare, pharmaceuticals, and public company governance. The leadership’s strategic vision centers on identifying a viable U.S.-focused pharmaceutical or healthcare manufacturing platform capable of scaling as a public company. Governance practices follow standard SPAC structures, including board oversight and shareholder approval requirements for a business combination.
Key executives and directors include:
- Scott J. Tarriff – Chief Executive Officer
- Jonathan Lieber – Chief Financial Officer
- Richard J. Purcell – Chairman of the Board
- John M. Stossel – Director
Leadership details, titles, and governance structures are verified through SEC filings, including the company’s registration statement and subsequent periodic reports.